Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer

At Zentalis, we are developing clinically differentiated therapeutics targeting fundamental cancer pathways that have the potential to address major unmet medical needs for patients with cancer. We have successfully advanced three compounds into the clinic in the Company’s first five years, all internally developed using the deep chemistry capabilities of our integrated discovery engine.


Anthony Sun, MD

Chairman & Chief Executive Officer

Kevin Bunker, PhD

Chief Operating Officer

Robert Winkler, MD

Chief Medical Officer

Melissa Epperly, MBA

Chief Financial Officer

Ahmed Samatar, PhD

Sr. Vice President, Oncology Research

Peter Huang, PhD

Vice President, Chemistry

Meena Rao, PhD

VP, Regulatory Affairs & Quality Assurance

Orna Bornstein, PhD

Vice President, Clinical Operations

Kimberley Overs, JD

Vice President, General Counsel

Lawrence Cripe

Director of Corporate Development

Board Of Directors

David Goel

Matrix Capital Management

Dave Johnson


Rohan Nirody

Viking Global Investors
Board Observer

Karan Takhar

Matrix Capital Management

Cam Gallagher, MBA

Executive Director

Anthony Sun, MD

Chairman & Chief Executive Officer

Scientific Advisory Board

Andrew Badley, MD

Mayo Clinic

Shaji Kumar, MD

Mayo Clinic

Anthony Letai, MD, PhD

Harvard Medical School

Ross Levine, MD

Memorial Sloan Kettering Cancer Center

Donald McDonnell, PhD

Duke University

Jun Qi, PhD

Harvard Medical School

Kwok-Kin Wong, MD, PhD

NYU Langone Health

Business Advisory Board

Rob Glassman, MD

Credit Suisse

Chad Robins, MBA

Adaptive Biotechnologies


Accelerating Broad Oncology Pipeline



Supporting Publications

View Supporting Publications

Partners & Collaborations

Pfizer logo

SciClone logo

mayo clinic logo

Please contact us at to discuss partnering and collaborations opportunities.

Our mission is to deliver revolutionary medicines to cancer patients. 


We share a passion for improving the lives of patients with cancer. Our driving goal is to discover and develop breakthrough medicines. Our collaborative team brings deep scientific, clinical, business and leadership expertise, and we invite you to join us! It takes a team of empowered individuals with diversity of thought, skills, passions and backgrounds to discover drugs and deliver novel therapeutics to help patients with cancer.


Partnering with an outstanding group of leading healthcare investors to drive forward best-in-class chemistry for cancer patients.

Matrix Capital Management logo

Viking Global Investor LP logo

red mile group logo

perceptive advisors logo

surveyor logo

eventide logo

mayo clinic logo

alexandria logo

pharamon logo

highlight capital logo


Corporate Office
530 Seventh Avenue
Suite 2201
New York, NY 10018 

Science Center
10835 Road to the Cure
Suite 205
San Diego, CA 92121

For more information